Published Paper Details:

Dapagliflozin (Farxiga), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has emerged as a critical therapeutic option for managing type 2 diabetes mellitus and heart failure. This review evaluates the pharmacological mechanisms, clinical efficacy, and safety profile of dapagliflozin. By promoting urinary glucose excretion and lowering blood glucose levels, dapagliflozin effectively improves glycemic control in diabetic patients. Recent clinical trials have also demonstrated its significant benefits in reducing hospitalization rates for heart failure and improving overall cardiovascular outcomes, even in patients without diabetes. The drug's favorable renal protective effects further underscore its multifaceted role in managing comorbid conditions. However, potential adverse effects, such as urinary tract infections and dehydration, necessitate careful patient selection and monitoring. This review aims to provide a comprehensive overview of the current evidence surrounding dapagliflozin, highlighting its dual benefits in diabetes management and heart failure, as well as implications for clinical practice.